Real World Insights: Bispecific Antibodies in R/R MM
Douglas Sborov, MD; Mary Steinbach, NP; and Kelley Julian, PharmD, BCOP, discuss 3 complex cases of patients with myeloma with late-line, heavily pretreated disease and why they opted to treat these patients with BCMA- and GPRC5D-directed bispecifics. They also focus on expected toxicities and supportive care strategies to maximize patient tolerability of R/R MM treatment drugs and drug sequencing in patients who are difficult to treat.
EP. 1: Meet a 76-Year-Old Patient With Late-Line R/R MM, Unsuitable For CAR T Therapy
December 13th 2024Panelists discuss how patient 1 is a 76-year-old female with unknown- stage R-ISS, oligosecretory IgG-K/KLC MM currently treated with talquetamab. One year following the talquetamab initiation, she is in VGPR/MRD- (likely CR or sCR as IFE positive is LLC and she has KLC). To spare toxicity physicians have decreased her dosing to monthly, starting with cycle 14 day 1.
